FY2025 Earnings Forecast for Omeros Issued By HC Wainwright

Omeros Co. (NASDAQ:OMER - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings per share estimates for Omeros in a research report issued on Tuesday, June 10th. HC Wainwright analyst B. Folkes expects that the biopharmaceutical company will post earnings of ($1.78) per share for the year. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, May 16th. Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Finally, D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Omeros presently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

Omeros Stock Down 4.2%

NASDAQ OMER traded down $0.15 during trading hours on Thursday, hitting $3.40. 696,461 shares of the company were exchanged, compared to its average volume of 689,598. The stock has a 50-day moving average price of $5.11 and a 200 day moving average price of $7.71. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60. The stock has a market cap of $199.22 million, a PE ratio of -1.47 and a beta of 2.20.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Institutional Trading of Omeros

Large investors have recently modified their holdings of the company. Truvestments Capital LLC boosted its holdings in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC raised its stake in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in Omeros in the fourth quarter worth approximately $46,000. Picton Mahoney Asset Management raised its stake in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 4,404 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Omeros by 14,486.3% in the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,388 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.